Protein Summary
This gene encodes dystrobrevin beta, a component of the dystrophin-associated protein complex (DPC). The DPC consists of dystrophin and several integral and peripheral membrane proteins, including dystroglycans, sarcoglycans, syntrophins and dystrobrevin alpha and beta. The DPC localizes to the sarcolemma and its disruption is associated with various forms of muscular dystrophy. Dystrobrevin beta is thought to interact with syntrophin and the DP71 short form of dystrophin. [provided by RefSeq, Mar 2016]
- ENST00000404103
- ENSP00000385482
- ENSG00000138101
- ENST00000405222
- ENSP00000384787
- ENST00000406818
- ENSP00000384084
- ENST00000407038
- ENSP00000384767
- ENST00000407661
- ENSP00000385193
- ENST00000496972
- ENSP00000444463
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
transcription factor | 0.84 | ||
histone modification site profile | 0.8 | ||
kinase perturbation | 0.76 | ||
transcription factor binding site profile | 0.76 | ||
trait | 0.75 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 15.2 (req: < 5)
Gene RIFs: 4 (req: <= 3)
Antibodies: 234 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 15.2 (req: >= 5)
Gene RIFs: 4 (req: > 3)
Antibodies: 234 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Term: 1
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0